Relmada Therapeutics (4E2) Stock Overview
Operates as a clinical-stage biotechnology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
4E2 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Relmada Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.51 |
| 52 Week High | US$0.70 |
| 52 Week Low | US$0.21 |
| Beta | 0.66 |
| 1 Month Change | -17.74% |
| 3 Month Change | 109.02% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4E2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.0% | -0.5% | 2.5% |
| 1Y | n/a | -20.1% | 17.1% |
Return vs Industry: Insufficient data to determine how 4E2 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4E2 performed against the German Market.
Price Volatility
| 4E2 volatility | |
|---|---|
| 4E2 Average Weekly Movement | 32.0% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in DE Market | 12.2% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 4E2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4E2's weekly volatility has increased from 24% to 32% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 17 | Sergio Traversa | www.relmada.com |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease.
Relmada Therapeutics, Inc. Fundamentals Summary
| 4E2 fundamental statistics | |
|---|---|
| Market cap | €16.92m |
| Earnings (TTM) | -€64.28m |
| Revenue (TTM) | n/a |
Is 4E2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4E2 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$75.71m |
| Earnings | -US$75.71m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4E2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/01 08:26 |
| End of Day Share Price | 2025/06/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Relmada Therapeutics, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Lin Tsai | Jefferies LLC |
| Marc Goodman | Leerink Partners LLC |